⏱️ The next cancer cure is on hold. ⁦‪@NIH‬⁩ grants invest in future science gains that pay back for our citizens at a rate of more than 2:1 in economic activity. We are losing the battle for discovery.

#SABCS24 #bcsm #OncSky #MedSky Following up with a few resources from FDA-@abreastcancer session today for #breastcancer #advocacy community Someone asked for email to report misleading drug ads: [email protected] /1 @oncoalert.bsky.social

Something sounds different in this #SABCS24 session. The science here is a little more engaging 😁.

PRACTICE CHANGING findings from PATINA presented by Dr. Metzger from @dfcibreastonc.bsky.social - n=518 HR+/HER2+ mBC - all received THP followed by HP+ET +/- palbo - PFS was 29 vs 44 months with palbo - Tox consistent with prior studies

Hyping for my smart dear friend @yabdoumd.bsky.social from UNC, who is moderating Poster Spotlight Session 9: ctDNA Uses for Minimal Residual Disease Testing, Tumor Evolution, and Novel Technologies. Tomorrow at 7 AM at Stars at Night 3-4 #SABCS2024 #bcsm @sabcs.bsky.social

Absolutely important. “Shared” decision requires active effort by oncologists to simplify, relate and iterate findings, while not encumbering patients with nuances.

Another great study run by TBCRC and lead by my dear colleague Dr. Julie Nangia at @bcmhouston.bs. #042 used Ruxolitinib for 10-20 days b4 surgery to inhibit pSTAT5 pathway in premalig AH/CIS (ductal/lobular). 1ry endpoint is apoptosis by Caspase3 drop pending. Congrats #SABCS24 #bcsm

Sobering data on 7-year IBC outcome from @mdanderson.bsky.social presented by superstar Dr. Azadeh Nasrazadani. 7-year OS % 7, 24, 50, 55 in TNBC, ER+ HER2-, ER- HER2+ and ER+HER2+. CDK4/6i benefit low compared with historic cohorts. @naborala.bsky.social we need better Rx. #SABCS24 #bcsm

“It is impressive that the combination [of imlunestrant and abemaciclib] seems to tower above the rest” — @DrHalBurstein sharing his self-proclaimed dreaded cross trial comparison (students, biostatisticians: *avert your eyes*) #SABCS24 @oncoalert.bsky.social

#EMBER3 Imlunestrant (oral SERD) beats fulv (88% of SOC ET) in 2nd line ER+ #bcsm only in those with ESR1 mut However, combo of Imlunestrant + abema wins in all-comers 5.5 vs. 9.5 mo regardless of ESR1 * note prior CDK not required #SABCS24 @sabcs.bsky.social @oncoalert.bsky.social

A nice poster on TDxD resistance presented by my dear friend Mohamed Gouda from MDACC. Almost 1/3rd of Pts lost HER2 IHC, and another 1/3 decreased transcript. Did PAM50 change? #SABCS24 #bcsm

10 year follow up on OlympiA shows persistent benefit in iDFS, OS. #SABCS24 @oncoalert.bsky.social

Dr Luca Malorni presented very thought provoking TOUCH study in ER/HER2+ with neoadj HP/Taxol vs HP/Palbo Letrozole. pCR 32.9 vs 33.3%. In high RBsig, Palbo/AI did better! Another no-chemo Rx next to KRISTINE. Qs: PAM50 role? CDK/ET replacing Taxol in NACT? What about CDK in ABC? #SABCS24 #bcsm

Great data on PADMA presented by Dr. Loibl in 1st L HR+ MBC btw Chemo + maintenance ET vs. Palbo + ET. Palbo more than doubled time to treatment failure (6 vs 17 months) Same data in RIGHT CHOICE with PFS 21.8 vs 12.8 months in RiboET vs CT. No more chemo 1st L! #SABCS24 #bcsm @sabcs.bsky.social

Great stepwise approach. Also good reminder that topical estrogen therapy did NOT demonstrate increased risk of recurrences per multiple trials incl Cold et al JNCI 2022 and metaanalysis by Beste et al AJOG 2024 #sabcs24 #bcsm

An important money slide in discordance of variants between cfDNA and tumor testing. Panel by stellar Dr. Ellen Landsberger who shared some tough Qs on utility of cfDNA from Pt advocates POV. Take home: Breast CA has high rate of novel variants on cfDNA not on tumor #SABCS24 @sabcs.bsky.social

OFS for fertility perservation is severely underutilized. AYA discussion with young Pts is paramount & need routine workflow On separate note, there remains a gap in using OFS for HR+ HER2+. Data are a little different (T/OFS better than E/OFS) but they were small percent of population. #SABCS24

Everyday there is at least one TBCRC presentation in #SABCS24. Such a wonderful consortium and amazing dedicated investigators. Since inception, 64 breast trials (and counting). @hoperugo.bsky.social @ptarantinomd.bsky.social @meghanflanigan.bsky.social #bcsm

I have to salute #SABCS24 on the amazing tech platform site and app at events.hubilo.com/sabcs2024/home and at play.google.com/store/apps/d.... The live streaming, almost instant replayability of sessions, note-taking. Please make best use of the site/app (especially for live viewing)

This was a wonderful session. Highly recommend to rewatch for those who have tough time where to start applying for funds. Foundational, NIH, and industry venues. Also internal CCSG funds and SPORE CDA. @stolaney1.bsky.social @Minetta Liu, @Larissa Korde @Brenda Ernst #SABCS24 #bcsm

Impressive work by SWOG and RxPONDER team including Kevin Kalinsky and my dear friend Yara Abdou. Both IDFS & DRFS worse for black Pts vs. whites (91.6% vs 87.1% & 95.8% vs 91.0%). Chemotherapy efficacy is same. BMI played role in outcome @oncoalert.bsky.social #bcsm #oncosky. tinyurl.com/eptu2pap

Genome-wide association analyses in Nature Genetics provide insights into the molecular etiology of dilated cardiomyopathy, which may inform the design of genetic testing strategies and may facilitate the development of targeted therapeutics. https://go.nature.com/4fIkNmh 🧪

Come join me Thursday morning Dec 12 as I discuss these wonderful 4 poster highlights #sabcs24 #survonc #bcsm @sabcs.bsky.social

My feed is filled with misinformation re: aid in dying. A fewcpoints to clear up. #medsky #oncsky 1. Where it's legal, a physician cannot assist. That is, the person with a terminal dx opting to die must administer meds to self- no help. Hence, it isn't physician assisted suicide 1/5

Nice data from a mouse model. Would love to see more prospective studies in humans on caloric restriction impacting pathological complete response in breast cancer. Current data is limited.

Impact of cycle 1 irAEs on ICI outcomes: - 683pts from SWOG DART trial - g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001 - g3+ irAEs = ⬇️OS HR  1.41 p= .025 - g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002 Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social academic.oup.com/jnci/advance...